

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1 – 24 (Cancelled).

25. (Previously presented) An isolated [[A]] retroviral packaging cell for transforming a quiescent cell with a nucleic acid encoding a polypeptide, said retroviral packaging cell comprising:

(a) a retroviral vector, and

(b) an exogenous nucleic acid encoding a stem cell [[growth]] factor, wherein said stem cell [[growth]] factor is displayed on the surface of said retroviral packaging cell, wherein said retroviral vector comprises said nucleic acid encoding said polypeptide, and wherein said stem cell [[growth]] factor displayed on the surface of said retroviral packaging cell can induce said quiescent cell to divide, so that said nucleic acid encoding said polypeptide can be incorporate into the genome of said quiescent cell.

26. (New) The cell of claim 25, wherein said quiescent cell is a hematopoietic stem cell.

27. (New) The cell of claim 25, wherein said stem cell factor is expressed as an N-terminal fusion protein with a retroviral envelope protein.

28. (New) The cell of claim 27, wherein said retroviral envelope protein is viral envelope SU protein.

29. (New) The cell of claim 25, wherein said stem cell factor is expressed as a fusion protein with a viral envelope protein and is fused to the envelope protein via a cleavable linker.